Medicine Stocks Based on Big Data Analytics: Returns up to 684.62% in 3 Months

Medicine Stocks

The Medicine Stocks Package is designed for investors and analysts who need predictions for the best stocks to buy in the Medicine Industry. It includes 20 stocks with bullish and bearish signals and indicates the best medicine stocks to trade:

  • Top 10 Medicine stocks for the long position
  • Top 10 Medicine stocks for the short position


Package Name: Medicine Stocks
Recommended Positions: Long
Forecast Length: 3 Months (3/24/2020 – 6/24/2020)
I Know First Average: 96.89%
Medicine Stocks
Medicine Stocks chart

The algorithm correctly predicted 8 out 10 of the suggested trades in the Medicine Stocks Package for this 3 Months forecast. The top performing prediction from this package was CLDX with a return of 684.62%. SRPT and FOLD saw outstanding returns of 83.07% and 71.61%. With these notable trade returns, the package itself registered an average return of 96.89% compared to the S&P 500’s return of 36.33% for the same period.

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.